Carotid Intima media-thickness and genes involved in lipid metabolism in diabetic patients using statins - a pathway toward personalized medicine

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 11, Issue 1, 2013, Pages 3-8

  Starčević, Jovana Nikolajević ^a   Petrovič, Danijel ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

B mode ultrasound; Carotid atherosclerosis; Carotid intima media thickness; Epigenetics; Gene polymorphisms; Intervention trials; Personalized medicine; Statins; Therapeutic efficacy assessment; Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN A5; APOLIPOPROTEIN B; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTATHIONE TRANSFERASE M1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER TRIACYLGLYCEROL LIPASE; PHOSPHOPYRUVATE CARBOXYLASE; PRAVASTATIN;

ALLELE; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CLINICAL PRACTICE; DRUG EFFICACY; ECHOGRAPHY; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEREDITY; HUMAN; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM;

CAROTID INTIMA-MEDIA THICKNESS; DIABETES MELLITUS, TYPE 2; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDIVIDUALIZED MEDICINE; LIPID METABOLISM; POLYMORPHISM, GENETIC; TREATMENT OUTCOME;

EID: 84873143754     PISSN: 18715257     EISSN: 18756182     Source Type: Journal    
DOI: 10.2174/1871525711311010003     Document Type: Article

References (49)

1. Poredos, P. Intima-media thickness: indicator of cardiovascular risk and measure of the extent of atherosclerosis. Vasc. Med., 2004, 9(1), 46-54.
2. Stein, J.H.; Korcarz, C.E.; Post, W.S. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: summary and discussion of the American Society of Echocardiography consensus statement. Prev. Cardiol., 2009, 12(1), 34-38.
3. Zannad, F.; Sass, C.; Visvikis, S. Environmental and genetic determinants of intima-media thickness of the carotid artery. Clin. Exp. Pharmacol. Physiol., 2001, 28(12), 1007-1010.
4. Coll, B.; Nambi, V.; Feinstein, S.B. New advances in noninvasive imaging of the carotid artery: CIMT, contrast-enhanced ultrasound, and vasa vasorum. Curr. Cardiol. Rep., 2010, 12(6), 497-502.
5. Grundy, S.M.; Pasternak, R.; Greenland, P.; Smith, S. Jr.; Fuster, V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation, 1999, 100(13), 1481-1492.
6. Chamnan, P.; Simmons, R.K.; Sharp, S.J.; Griffin, S.J.; Wareham, N.J. Cardiovascular risk assessment scores for people with diabetes: a systematic review. Diabetologia, 2009, 52(10), 2001-2014.
7. Sharma, K; Blaha, M.J.; Blumenthal, R.S.; Musunuru, K. Clinical and research applications of carotid intima-media thickness. Am. J. Cardiol., 2009, 103(9), 1316-1320.
8. Stein, J.H. Carotid intima-media thickness and vascular age: you are only as old as your arteries look. J. Am. Soc. Echocardiogr., 2004, 17(6), 686-689.
9. Ferrières, J.; Elias, A.; Ruidavets, J.B.; Cantet, C.; Bongard, V.; Fauvel, J.; Boccalon, H. Carotid intima-media thickness and coronary heart disease risk factors in a low-risk population. J. Hypertens., 1999, 17(6), 743-748.
10. Li, S.; Chen, W.; Srinivasan, S.R.; Bond, M.G.; Tang, R.; Urbina, E.M.; Berenson, G.S. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA, 2003, 290(17), 2271-2276.
11. Folsom, A.R.; Eckfeldt, J.H.; Weitzman, S.; Ma, J.; Chambless, L.E.; Barnes, R.W.; Cram, K.B.; Hutchinson, R.G. Relation of carotid artery wall thickness to diabetes mellitus, fasting glucose and insulin, body size, and physical activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Stroke, 1994, 25(1), 66-73.
12. Agewell, S.; Wilkstrand, J.; Samuelsson, O.; Persson, B.; Andersson, O.K.; Fagerberg, B. The eficacy of multiple risk factor intervention in treated hypertensive men during long-term follow up. Risk Factor Intervention Study Group. J. Intern. Med., 1994, 236(6), 651-659.
13. O'Leary, D.; Polak, J.; Kronmal, R.; Manolio, T.; Burke, G.; Wolfson, S. Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults: Cardiovascular Health Study. N. Engl. J. Med., 1999, 340(1), 14-22.
14. Bots, M.L.; Hoes, A.W.; Koudstaal, P.J.; Hofman, A.; Grobbee, D.E. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation, 1997, 96(5), 1432-1437.
15. Chambless, L.E.; Heiss, G.; Folsom, A.R.; Rosamond, W.; Szklo, M.; Sharrett, A.R.; Clegg, L.X. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Am. J. Epidemiol., 1997, 146(6), 483-494.
16. Lorenz, M.W.; Markus, H.S.; Bots, M.L.; Rosvall, M.; Sitzer, M. Prediction of clinical cardiovascular events with carotid intimamedia thickness: a systematic review and meta-analysis. Circulation, 2007, 115(4), 459-467.
17. Paternoster, L.; Martinez-Gonzalez, N.A.; Charleton, R.; Chung, M.; Lewis, S.; Sudlow, C.L. Genetic effects on carotid intimamedia thickness: systematic assessment and meta-analyses of candidate gene polymorphisms studied in more than 5000 subjects. Circ. Cardiovasc. Genet., 2010, 3(1), 15-21.
18. Zannad, F.; Benetos, A. Genetics of intima-media thickness. Curr. Opin. Lipidol., 2003, 14(2), 191-200.
19. Xiang, A.H.; Azen, S.P.; Buchanan, T.A.; Raffel, L.J.; Tan, S.; Cheng, L.S.; Diaz, J.; Toscano, E.; Quinonnes, M.; Liu, C.R.; Liu, C.H.; Castellani, L.W.; Hsueh, W.A.; Rotter, J.I.; Hodis, H.N. Heritability of subclinical atherosclerosis in latino families ascertained through a hypertensive parent. Arterioscler. Thromb. Vasc. Biol., 2002, 22(5), 843-848.
20. Malin, R.; Loimaala, A.; Nenonen, A.; Mercuri, M.; Vuori, I.; Pasanen, M.; Oja, P.; Bond, G.; Koivula, T.; Lehtimäki, T. Relationship between high-density lipoprotein paraoxonase gene M/L55 polymorphism and carotid atherosclerosis differs in smoking and nonsmoking men. Metabolism, 2001, 50(9), 1095-1101.
21. Rundek, T.; Elkind, M.S.; Pittman, J.; Boden-Albala, B.; Martin, S.; Humphries, S.E.; Juo, S.H.; Sacco, R.L. Carotid intima-media thickness is associated with allelic variants of stromelysin-1, interleukin-6, and hepatic lipase genes: the Northern Manhattan Prospective Cohort Study. Stroke, 2002, 33(5), 1420-1423.
22. Karvonen, J.; Kauma, H.; Kervinen, K.; Rantala, M.; Ikäheimo, M.; Päivänsalo, M.; Savolainen, M.J.; Kesäniemi, Y.A. Endothelial nitric oxide synthase gene Glu298Asp polymorphism and blood pressure, left ventricular mass and carotid artery atherosclerosis in a population-based cohort. J. Intern. Med., 2002, 251(2), 102-110.
23. de Waart, F.G.; Kok, F.J.; Smilde, T.J.; Hijmans, A.; Wollersheim, H.; Stalenhoef, A.F. Effect of glutathione S-transferase M1 genotype on progression of atherosclerosis in lifelong male smokers. Atherosclerosis, 2001, 158(1), 227-231.
24. Chapman, C.M.; Palmer, L.J.; McQuillan, B.M.; Hung, J.; Burley, J.; Hunt, C.; Thompson, P.L.; Beilby, J.P. Polymorphisms in the angiotensinogen gene are associated with carotid intimal-medial thickening in femals from a community-based population. Atherosclerosis, 2001, 159(1), 209-217.
25. Schmidt, H.; Schmidt, R.; Niederkorn, K.; Gradert, A.; Schumacher, M.; Watzinger, N.; Hartung, H.P.; Kostner, G.M. Paraoxonase PON1 polymorphism leu-Met54 is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. Stroke, 1998, 29(10), 2043-2048.
26. Willeit, J.; Kiechl, S.; Oberhollenzer, F.; Rungger, G.; Egger, G.; Bonora, E.; Mitterer, M.; Muggeo, M. Distinct risk profiles of early and advanced atherosclerosis: prospective results from the Bruneck Study. Arterioscler. Thromb. Vasc. Biol., 2000, 20(2), 529-537.
27. Pfohl, M.; Fetter, M.; Koch, M.; Barth, C.M.; Rudiger, W.; Haring, H.U. Association between angiotensin I-converting enzyme genotypes, extracranial artery stenosis, and stroke. Atherosclerosis, 1998, 140(1), 161-166.
28. Pallaud, C.; Sass, C.; Zannad, F.; Siest, G.; Visvikis, S. APOC3, CETP, fibrinogen and MTHFR are genetic determinants of carotid intima-media thickness in supposed healthy men (the Stanislas cohort). Clin. Genet., 2001, 59(5), 316-324.
29. Kohara, K.; Tabara, Y.; Yamamoto, Y.; Igase, M.; Nakura, J.; Miki, T. Genotype-specific association between circulating soluble cellular adhesion molecules and carotid intimamedia thickness in community residents: J-SHIPP study. Shimanami Health Promoting Program. Hypertens. Res., 2002, 25(1), 31-39.
30. Hegele, R.A.; Al-Shali, K.Z.; House, A.A.; Hanley, A.J.; Harris, S.B.; Mamakeesick, M.; Fenster, A.; Zinman, B.; Cao, H.; Spence, J.D. Disparate associations of a functional promoter polymorphism in PCK1 with carotid wall ultrasound traits. Stroke, 2005, 36(12), 2566-2570.
31. Spence, J.D.; Hegele, R.A. Noninvasive phenotypes of atherosclerosis: similar windows but different views. Stroke, 2004, 35(3), 649-653.
32. Spence, D.J. Technology Insight: ultrasound measurement of carotid plaque-patient management, genetic research, and therapy evaluation. Nat. Clin. Pract. Neurol., 2006, 2(11), 611-619.
33. Baigent, C.; Keech, A.; Kearney, P.M.; Blackwell, L.; Buck, G.; Pollicino, C.; Kirby, A.; Sourjina, T.; Peto, R.; Collins, R.; Simes, R. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90 056 participants in 14 randomised trials of statins. Lancet, 2005, 366(9493), 1267-1268.
34. Sever, P.S.; Dahlöf, B.; Poulter, N.R.; Wedel, H.; Beevers, G.; Caulfield, M.; Collins, R.; Kjeldsen, S.E.; Kristinsson, A.; McInnes, G.T.; Mehlsen, J.; Nieminen, M.; O'Brien, E.; Ostergren, J.; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 2003, 361(9364), 1149-1158.
35. Mangravite, L.M.; Thorn, C.F.; Krauss, R.M. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J., 2006, 6(6), 360-374.
36. Kitzmiller, J.P.; Groen, D.K.; Phelps, M.A.; Sadee, W. Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others. Cleve. Clin. J. Med., 2011, 78(4), 243-257.
37. Maggo, S.D.; Kennedy, M.A.; Clark, D.W. Clinical implications of pharmacogenetic variation on the effects of statins. Drug Saf., 2011, 34(1), 1-19.
38. Espeland, M.A.; O'leary, D.H.; Terry, J.G.; Morgan, T.; Evans, G.; Mudra, H. Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. Curr. Control. Trials Cardiovasc. Med., 2005, 6(1), 3.
39. Hubacek, J.A.; Vrablik, M. Effect of apolipoprotein E polymorphism on statin-induced decreases in plasma lipids and cardiovascular events. Drug. Metabol. Drug. Interact., 2011, 26(1), 13-20.
40. Volcik, K.A.; Barkley, R.A.; Hutchinson, R.G.; Mosley, T.H.; Heiss, G.; Sharrett, A.R.; Ballantyne, C.M.; Boerwinkle, E. Apolipoprotein E polymorphisms predict low density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participants. Am. J. Epidemiol., 2006, 164(4), 342-348.
41. Hubacek, J.A.; Adamkova, V.; Prusikova, M.; Snejdrlova, M.; Hirschfeldova, K.; Lanska, V.; Ceska, R.; Vrablik, M. Impact of apolipoprotein A5 variants on statin treatment efficacy. Pharmacogenomics, 2009, 10(6), 945-950.
42. Qiao, Y.; Liu, R.; Tian, H.M.; Liu, Y.; Qiang, O.; Liu, B.W. Association of apolipoprotein A5 gene-1131T/C polymorphism with serum lipids and carotid intima-media thickness in patients with type 2 diabetes mellitus. Sichuan Da Xue Xue Bao Yi Xue Ban, 2008, 39(6), 965-968.
43. Ye, P.; Shang, Y.; Ding, X. The influence of apolipoprotein B and E gene polymorphisms on the response to simvastatin therapy in patients with hyperlipidemia. Chin. Med. Sci. J., 2003, 18(1), 9-13.
44. Nieminen, T.; Kähönen, M.; Islam, S.; Raitakari, O.T.; Hutri-Kähönen, N.; Marniemi, J.; Juonala, M.; Rontu, R.; Viikari, J.; Lehtimäki, T. Apolipoprotein A-I/C-III/A-IV SstI and apolipoprotein B XbaI polymorphisms do not affect early functional and structural changes in atherosclerosis: the Cardiovascular Risk in Young Finns study. Circ J., 2007, 71(5), 741-745.
45. Lahoz, C.; Peña, R.; Mostaza, J.M.; Laguna, F.; García-Iglesias, M.; Taboada, M.; Pintó, X.; RAP Study Group. The-514C/T polymorphism of the hepatic lipase gene significantly modulates the HDL-cholesterol response to statin treatment. Atherosclerosis, 2005, 182(1), 129-134.
46. Salazar, L.A.; Hirata, M.H.; Quintão, E.C.; Hirata, R.D. Lipidlowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low-density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia. J. Clin. Lab. Anal., 2000, 14(3), 125-131.
47. Koeijvoets, K.C.; Rodenburg, J.; Hutten, B.A.; Wiegman, A.; Kastelein, J.J.; Sijbrands, E.J. Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trial. Circulation, 2005, 112(20), 3168-3173.
48. Thompson, J.F.; Hyde, C.L.; Wood, L.S.; Paciga, S.A.; Hinds, D.A.; Cox, D.R.; Hovingh, G.K.; Kastelein, J.J. Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort. Circ. Cardiovasc. Genet., 2009, 2(2), 173-181.
49. Rosenson, R.S. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis, 2004, 173(1), 1-12.